Specialists in the discovery of epigenetic biomarkers and the development of clinical diagnostic assays take up residence in the Trinity Building.

Chesterford Research Park is delighted to confirm the arrival of Cambridge Epigenetix on site. The organisation, whose mission is to harness the power of epigenetics to develop the next generation of diagnostics and therapeutics, has moved into the 15,000 sq ft Trinity Building at the Park.

Spun-out of the University of Cambridge in 2012, Cambridge Epigenetix was founded by Professor Sir Shankar Balasubramanian (co-inventor of the Solexa/Illumina sequencing-by-synthesis platform) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which has enabled researchers to prove the link between epigenetic DNA modifications and disease.  

The move to Chesterford unites the current team under one roof and will facilitate the rapid growth of the organisation as it focuses on the utilisation of its proprietary epigenetic discovery platforms to develop improved diagnostic tests, both in house and in partnership with leading biopharma companies.

Dr Jason Mellad, CEO, Cambridge Epigenetixcommented of the move: “We are committed to delivering on the promise of epigenetics to improve human health. The move to Chesterford Research Park is a vital component of our strategy, providing us with state-of-the-art facilities and importantly the space to grow as we expand our biomarker discovery capabilities.

We are extremely excited by this next stage in the company’s development as we apply our disruptive technologies to develop improved, minimally invasive diagnostic and prognostic tests for accurate and early detection of cancer and other diseases.

For more information about Cambridge Epigenetix please click here.